Ardelyx Just Posted a Record Quarter and the Market Yawned. Here's Why It Was Right To.

# Ardelyx Just Posted a Record Quarter and the Market Yawned. Here's Why It Was Right To.

Here's a fun exercise: report your best quarterly revenue ever, beat the top line by a mile, and watch your stock get taken out back anyway. That's the Ardelyx special, and it happened again on August 6.

The numbers looked great at first glance. $118.1 million in product revenue, up 31% year-over-year. IBSRELA doing $86.2 million, up 33%. XPHOZAH chipping in $31.9 million, up 27%. Biggest quarter in company history. If you stopped reading there, you'd think this was a buy.

Then you kept reading, and management cut full-year IBSRELA guidance from $410–$430 million down to $350–$370 million — a real, ~14% haircut at the midpoint — and quietly withdrew the long-term XPHOZAH targets that used to anchor the bull case (remember when this was supposed to be a $1 billion IBSRELA, $750 million XPHOZAH story?). That's not a footnote. That's the story.

The oversold setup is real. So is the reason for it.

RSI sitting around 18.66 is about as washed-out as a chart gets, and the stock is trading near 52-week lows around $4, well below both its 20-day and 50-day averages. I get why the "buy on weakness" crowd is circling — deeply oversold names bounce, that's just mean reversion 101, and one analyst out there is literally arguing the Medicare fight was lost but the growth trajectory wasn't.

But an oversold RSI is a description of price action, not a verdict on the business. And the business just told you, in plain English, that payor friction is compressing its best-selling drug's growth path — not a one-quarter blip, but bad enough to force a guidance cut just one quarter after management reiterated the old numbers. That's the tell. Q1 they said "we're good." Q2 they said "actually, no." When guidance moves that fast in that direction, you don't get to just assume it's the last cut.

And XPHOZAH's Medicare problem isn't a maybe anymore.

The appeals court dismissed Ardelyx's final challenge to CMS bundling XPHOZAH into the ESRD Prospective Payment System back in late June, and the stock dropped 8.4% on that news alone. That ruling is final. It structurally caps what XPHOZAH can earn from the Medicare/ESRD population — which is a big chunk of the addressable market for a phosphate-lowering drug in dialysis patients. Management responding by pulling long-term guidance rather than defending it tells you everything about how they view the damage.

Layer on an EPS miss (-$0.07 vs. -$0.05 expected), a negative 38% ROE, a negative operating margin, an active securities fraud class action alleging management misled investors on the pipeline, and heavy reliance on a single distributor, BioRidge, for commercial supply — and "record revenue" starts looking a lot less like a thesis and a lot more like a headline management needed you to see before you got to the guidance cut buried below it.

My take: this is a "sell the news" stock that keeps proving it deserves the label — it did the exact same thing after Q4 2025 results, dropping roughly 15% on a revenue beat. The pattern isn't random noise; it's the market pricing in that growth and guidance credibility are two different things at Ardelyx right now, and credibility is the one that's broken.

Could it bounce off an RSI this stretched? Sure, and if it does, don't be surprised. But a bounce off oversold conditions is a trade, not a conviction call, and this isn't a stock where I'd confuse the two. The real test isn't the next 10% move — it's whether Ardelyx can stop cutting guidance and start defending it. That test doesn't get graded until Q3 earnings come around on October 29.

Until then, this is a $281.8 million cash balance and a genuinely growing top line trying to outrun a payor system and a regulator that have both already said no. I'd want to see the growth story survive contact with reality at least once before I called the bottom.